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Cytomegalovirus (CMV) infection is common among infants of HIV-infected mothers in resource-limited settings. We exam-
ined the prevalence and timing of infant CMV infection during the first year of life using IgG antibody and avidity among HIV-
exposed infants in Malawi and correlated the results with the presence of detectable CMV DNA in the blood. The Breastfeeding,
Antiretrovirals and Nutrition (BAN) study randomized 2,369 mothers and their infants to maternal antiretrovirals, infant nevi-
rapine, or neither for 28 weeks of breastfeeding, followed by weaning. Stored plasma specimens were tested for CMV IgG and
antibody avidity from a random subset of infants who had been previously tested with blood CMV PCR and had available speci-
mens at birth and at 24 and 48 weeks of age. Ninety-four of 127 infants (74.0%) tested at 24 weeks of age had CMV IgG of low or
intermediate avidity, signifying primary CMV infections. An additional 22 infants (17.3%) had IgG of high avidity; 19 of them
had CMV DNA detected in their blood, indicating infant infections. Taken together, these results show that the estimated preva-
lence of CMV infection at 24 weeks was 88.9%. By 48 weeks of age, 81.3% of infants had anti-CMV IgG; most of them (70.9%)
had IgG of high avidity. The CMV serology and avidity testing, combined with the PCR results, confirmed a high rate of primary
CMV infection by 6 months of life among breastfeeding infants of HIV-infected mothers. The CMV PCR in blood detected most,
but not all, infant CMV infections.
Cytomegalovirus (CMV) infection is the most common con-genital infection, with an estimated prevalence of 1% in
resource-limited settings (1, 2). Approximately 10 to 20% of con-
genital CMV infections result in permanent deficits, including
sensorineural hearing loss, vision loss, and mental and develop-
mental disability (3). The postnatal acquisition of CMV can occur
through horizontal transmission and through breastfeeding, with
a high probability of transmission in infants fed with breast milk
containing infectious virus (4, 5). The infants of HIV-infected
mothers may have higher rates of congenital CMV infection, par-
ticularly if the mothers are immunocompromised (6). While post-
natal transmission is thought to be generally benign in healthy
full-term infants, premature infants or other groups of immuno-
compromised infants are at risk for more extensive disease and
may also experience long-term cognitive delays (7–9).
While the increased morbidity and mortality among infants
coinfected with HIV and CMV is well recognized (10–14), HIV-
exposed but uninfected infants may also be at increased risk for
morbidity and mortality from CMV infection (15–17). A study in
Zambia found that HIV-exposed infants who were CMV seropos-
itive had decreased length for age, reduced head size, and lower
psychomotor development than those who were CMV uninfected
(5). HIV is endemic in many African countries and the CMV
childhood infection burden is high, which may have a substantial
impact on child health in the region. It is therefore important to
examine when infants acquire primary CMV infection in such
settings.
In a previous analysis, we reported, using blood CMV PCR,
that 70% of infants of HIV-infected mothers had acquired CMV
infection by 24 weeks of age (18). Given that blood is not the
optimal sample source for CMV detection, it is possible that our
findings underestimated the true incidence of CMV acquisition in
the infants. We thus additionally performed CMV IgG antibody
titer and avidity testing in the infant plasma specimens at different
points in the infants’ first year of life. The objectives of this study
were to comprehensively assess the rate of CMV acquisition and to
further characterize the time of CMV infection in HIV-exposed
infants. Given the presence of maternal transplacentally acquired
antibody in the infant and the high prevalence of CMV immunity
among women in resource-limited settings, antibody avidity was
used as a tool to decipher the time of primary CMV infection in
the infants. We used samples collected and stored from infants
enrolled in the Breastfeeding, Antiretrovirals and Nutrition
(BAN) study (19), who breastfed for 28 weeks and were followed
for their first 48 weeks of life in Lilongwe, Malawi.
MATERIALS AND METHODS
Study population. The BAN study was a randomized controlled clinical
trial that evaluated, in a factorial design, the safety and efficacy of (i)
antiretroviral prophylaxis (a maternal triple-drug antiretroviral regimen
versus infant daily nevirapine administered during 28 weeks of breast-
feeding versus a control arm of only 1 week of antiretroviral prophylaxis
after delivery) and (ii) a maternal nutritional supplement during breast-
feeding in reducing postnatal mother-to-child HIV transmission and in
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enhancing maternal health during breastfeeding (19). The study random-
ized and followed 2,369 mother-infant pairs between 2004 and 2010 in
Lilongwe, Malawi; enrolled infants had to have a birth weight of at least
2,000 g and be HIV uninfected by 2 weeks of age.
We used stored infant plasma specimens from birth (28 specimens),
24 weeks of age (127 specimens), and 48 weeks of age (107 specimens),
randomly selected from a subset of 492 BAN study infants who had been
previously tested by CMV PCR in the plasma specimens or peripheral
blood mononuclear cells (PBMC) at 24 weeks of age (18). If infants tested
positive for CMV DNA at 24 weeks, they were also tested at birth; if they
tested negative for CMV DNA at 24 weeks, they were also tested at 48
weeks. This study was approved by the Malawi National Health Sciences
Research Committee and the institutional review boards of the University
of North Carolina at Chapel Hill and of the Centers for Disease Control
and Prevention.
CMV IgG and IgG avidity testing. IgG antibody against CMV was
measured in plasma specimens using the Vidas instrument (bioMérieux,
Lyon, France). Vidas performs an enzyme-linked fluorescent immunoas-
say that provides semiquantitative universal arbitrary units (UA) per mil-
liliter. IgG avidity testing was also performed using the Vidas reagents and
instrument. The avidity cutoff values were modified as described previ-
ously to provide improved sensitivity for identification of recent infec-
tion: 0.70 for low avidity (indicating recent infection), 0.70 to 0.79 for
intermediate avidity (indeterminate timing of infection), and 0.80 for
high avidity (indicating past infection) (20, 21). Validation of the avidity
cutoffs was done on serum specimens from individuals who were well
characterized regarding age, other risk for CMV infection, and IgG sero-
conversion. These specimens were tested for IgG avidity, and several cut-
off values were applied to determine the best separation of recent and past
infection (20, 21).
Statistical analysis. The IgG antibody titer and avidity index results
were described using medians and interquartile ranges (IQR) at each time
point. Spearman’s rank correlation coefficient was used to assess the cor-
relation between the IgG antibody level and avidity. The median IgG titer
and avidity index were compared by CMV PCR test result status using
Wilcoxon rank sum tests.
RESULTS
CMV IgG antibodies in the infants and their avidity at birth, 24
weeks, and 48 weeks. Of 28 samples tested by CMV serology at
birth (when most of the IgG in the infant is maternal), 27 (96.4%)
were positive for CMV IgG antibody, indicating a 96.4% preva-
lence of CMV immunity among the mothers. Of these IgG-posi-
tive samples, a subset of 20 with enough sample available were
tested for IgG avidity; 19 (95.0%) of them had high avidity, signi-
fying past maternal infection and transplacentally transferred ma-
ternal antibody (Table 1 and Fig. 1).
At 24 weeks of age, 116/127 (91.3%) samples tested were pos-
itive for CMV IgG. At this time point, only 19% of the positive
samples had IgG of high avidity; 36.2% had IgG of low avidity, and
44.8% had IgG of intermediate avidity (Fig. 1).
At 48 weeks of age, 87/107 (81.3%) samples had anti-CMV IgG
detected. The majority (70.9%) of these samples had antibody of
high avidity; 8.1% had antibody of low avidity and 20.9% of in-
termediate avidity (Table 1 and Fig. 1).
The median IgG antibody levels for those testing positive for
CMV IgG were 74.0 UA/ml at birth, 90.5 UA/ml at 24 weeks, and
93.0 UA/ml at 48 weeks (Table 1).
There was a significant correlation between the higher IgG anti-
body levels and increasing avidity at 24 and 48 weeks (Spearman’s
correlation coefficient, r  0.53 at 24 weeks; P  0.001; r  0.60 at 48
weeks, P  0.001) but not at birth (r  0.12; P  0.63) (Fig. 1).
Comparison of anti-CMV antibody with CMV PCR results.
As previously described, eight infants had CMV DNA detected in
the blood at birth (18). Of these, six had anti-CMV IgG of high
avidity, indicating prior maternal infection; one infant had IgG of
low avidity, indicating in utero infant infection with primary ma-
ternal infection, and one did not have CMV IgG, which is difficult
to explain and could be a specimen labeling or laboratory error.
Of the 116 samples that were positive for CMV IgG at 24 weeks,
83 were also positive for CMV by blood PCR at the same time
point (Table 2). Of the 22 samples that were positive for CMV IgG
and had high-avidity IgG, 19 infants also had CMV DNA detected
by PCR, signifying infant infection. For the remaining three in-
fants, the high-avidity anti-CMV IgG could represent either per-
sistence of maternal antibody or primary infant infection that oc-
curred more than 3 to 4 months earlier. If we exclude these three
infants, whose CMV infection status is uncertain, 113 of the 127
infants with anti-CMV IgG at 24 weeks of age can be unequivo-
cally considered to have primary infant CMV infections. Thus,
TABLE 1 Infant CMV IgG levels and IgG avidity at birth and 24 and 48 weeks of age
Measurementa
Results at:
Birth 24 wks 48 wks
CMV IgG serology
No. of samples 28 127b 107
Positive (no. [%]) 27 (96.4) 116 (91.3) 87 (81.3)
Negative (no. [%]) 1 (3.6) 9 (7.1) 20 (18.7)
IgG antibody level (UA/ml)c
Median (IQR) 74.0 (59.0–109.0) 90.5 (69.5–116.0) 93.0 (73.0–115.0)
IgG avidity index
No. of samples 20 116 86
Median (IQR) 0.91 (0.88–0.95) 0.73 (0.66–0.78) 0.83 (0.78–0.88)
Low (no. [%]) 1 (5.0) 42 (36.2) 7 (8.1)
Intermediate (no. [%]) 0 52 (44.8) 18 (20.9)
High (no. [%]) 19 (95.0) 22 (19.0) 61 (70.9)
a CMV, cytomegalovirus; IQR, interquartile range; UA, universal arbitrary units.
b Two samples had equivocal results for IgG.
c Antibody level calculated for those positive by IgG serology.
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taking together the results of the CMV serology and the PCR test-
ing, we estimate the prevalence of infant CMV infection at 24
weeks to be 88.9%. Thirty cases of infant CMV infection not de-
tected by blood PCR were detected by IgG serology at 24 weeks
(representing a 23.6% increase in CMV detection by the CMV IgG
testing compared with that for blood PCR alone). No samples
were negative by CMV serology and positive by CMV PCR at 24
weeks.
At 48 weeks, 56 of the 87 samples positive for CMV IgG were
also positive by blood CMV PCR (Table 2). At this point, all of the
high-avidity antibodies are likely to be of infant origin and thus
can be assumed to be primary infant infections. Thirty-one infants
FIG 1 Association between CMV IgG antibody levels and CMV IgG avidity in infants of HIV-infected mothers in Lilongwe, Malawi, at birth and 24 and 48 weeks
of age. Low (0.70), intermediate (0.70 to 0.79) and high (0.79) avidity index values are indicated by different colors.
TABLE 2 CMV IgG and IgG avidity results compared with CMV PCR results in the blood of HIV-exposed, breastfeeding infants at 24 and 48 weeks of age
Measurementa
CMV PCR at 24 wks CMV PCR at 48 wks
Positive Negative P value Positive Negative P value
CMV IgG positive (no. of samples) 83 33 56 31
IgG antibody level (UA/ml)
Median (IQR) 95.0 (77.0–122.0) 73.0 (54.0–101.0) 0.005 96.5 (76.0–124.0) 90.0 (66.0–100.0) 0.09
Avidity index
No. of samples 83 33 55 31
Median (IQR) 0.74 (0.69–0.79) 0.68 (0.59–0.75) 0.01 0.84 (0.78–0.89) 0.83 (0.78–0.88) 0.35
Low 24 (28.9) 18 (54.5) 5 (9.1) 2 (6.5)
Intermediate 40 (48.2) 12 (36.4) 10 (18.2) 8 (25.8)
High 19 (22.9) 3 (9.1) 40 (72.7) 21 (67.7)
CMV IgG negative (no. of samples) 0 9 0 20
a CMV, cytomegalovirus; IQR, interquartile range; UA, universal arbitrary units.
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who were CMV infected as indicated by serology did not have
CMV DNA detected in the blood by PCR at 48 weeks (thus, serol-
ogy conferred a 35.6% increase in diagnostic sensitivity compared
with that for blood PCR testing). No samples were negative by
serology and positive by PCR at 48 weeks.
The median antibody levels were significantly higher among
infants with CMV DNA detected in their blood than in those in
whom CMV DNA was not detected at 24 weeks (P  0.005) but
not at 48 weeks (P  0.09) (Table 2).
Maturation of anti-CMV IgG in the infants and correlation
with DNA detection in the blood. Of the infants who had CMV
DNA detected in the blood at 24 weeks, almost half (48.2%) had
CMV IgG of intermediate avidity (median avidity index, 0.74)
(Table 2). Conversely, of the samples negative by PCR at 24 weeks,
the majority (54.5%) of the CMV IgG-positive samples had low-
avidity antibody (median avidity index, 0.68). The median IgG
avidity index was higher in CMV PCR-positive than in PCR-neg-
ative infants at 24 weeks of age (P  0.01) (Table 2). At 48 weeks,
of those with CMV DNA detected in the blood, the majority
(72.7%) had IgG of high avidity (median avidity index, 0.84). Of
those negative by CMV PCR but positive by serology at 48 weeks,
the majority (67.7%) also had high-avidity IgG (median avidity
index, 0.83) (Table 2). The median IgG avidity index did not differ
by PCR status at 48 weeks (P  0.35).
DISCUSSION
Almost all (96.4%) of the HIV-infected mothers in this setting had
evidence of prior CMV infection, as indicated by the presence of
anti-CMV IgG in the infants’ plasma at birth. Of interest, the
majority of infants with congenital infection in our study, as de-
termined by CMV DNA detection in the blood at birth (18), had
mothers with prior immunity to CMV. This is in line with other
findings suggesting that many congenital infections are the result
of maternal CMV reinfection or reactivation, rather than primary
infection (20).
The majority of infants in this study acquired CMV rapidly
during the first year of life. Using blood CMV PCR, we had previ-
ously detected CMV infection in 70% of the HIV-exposed infants
in this cohort by 24 weeks and in 78.5% by 48 weeks (18). The
results of the present study using CMV serology and avidity test-
ing, when combined with the PCR results, confirm a higher rate of
infection at 24 weeks (88.9%) and at 48 weeks (81%). Other stud-
ies have also shown very high rates of CMV infection in HIV-
exposed infants in resource-limited settings (5, 22).
IgG avidity offered additional information on the character of
the antibody detected and helped to determine whether the anti-
body was transplacentally acquired maternal antibody or whether
it was a result of infant infection. Low CMV IgG avidity is consid-
ered a reliable indicator of primary infection within the preceding
3 to 4 months, whereas high avidity excludes primary infection
within the preceding 3 months (23). The IgG avidity testing dem-
onstrated that by 24 weeks, more than one-third of the infants had
CMV IgG of low avidity and almost half of the infants had anti-
body of intermediate maturity. By 48 weeks, 70% of infants with
detectable anti-CMV IgG had mature antibody of high avidity. At
24 weeks, 20% of infants had IgG of high avidity, which could
represent either transplacentally acquired maternal antibody
or already mature infant antibody from primary infection. Our
results indicate that most maternal antibody has waned by 6
months, consistent with a study from China suggesting that the
maternally acquired anti-CMV IgG in infants disappears before 8
months of age (24); similarly, a study from Germany concluded
that maternal antibody against CMV decayed by 12 months (25).
Our findings confirm that lower IgG antibody avidity was as-
sociated with younger age and with lower antibody titers, as ex-
pected with primary infection and as has been previously observed
(26). However, the median CMV IgG level and avidity were higher
in infants who had CMV DNA detected in their blood than in
those who did not at 24 weeks of age (although not at 48 weeks).
This finding is surprising, as circulating levels of CMV and shed-
ding in body fluids are higher during acute infection (26, 27).
Nevertheless, CMV is primarily shed in other body fluids, such as
urine or saliva, and the CMV levels in the blood are generally lower
(27). Indeed, the CMV viral loads in the blood were quite low in
this group of infants (median, 176.4 copies/ml; IQR, 88.6 to 433.3
at 24 weeks of age) (18). It is possible that studying other body
fluids would lead to different results, as was found in another
study that examined saliva (27).
Viral cultures or PCRs on urine (28) or saliva (29) samples are
the gold standard methods for CMV detection. CMV DNA PCR is
used to detect clinically significant levels of CMV DNA in plasma,
such as with symptomatic CMV infection, a severe clinical course
(30), or sequelae such as hearing loss (31). Our findings indicate
that CMV PCR in the blood captures most, but not all, primary
infant CMV infections, as confirmed by CMV IgG serology re-
sults. Increases in diagnostic sensitivity of 24 and 36%, respec-
tively, were observed by using CMV IgG serology in addition to
CMV DNA testing in the blood at 24 and 48 weeks of age.
The strength of this study is that the use of multiple assays,
including CMV IgG serology and avidity testing and DNA detec-
tion in the blood, allowed precise determination of both the mag-
nitude of infant CMV infection in the study population and the
timing of such infection. Almost 90% of breastfeeding infants of
HIV-infected mothers in Malawi will have already acquired CMV
infection by 24 weeks of age. Given the emerging evidence on the
negative repercussions of CMV infection on the health of these
infants (5, 18), an antiviral approach to prevent or delay CMV
transmission through reductions in maternal shedding or the de-
velopment of a CMV vaccine administered very early in such set-
tings is worth further exploration.
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